Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 5/20 | 0.32 |
| ▸ | FLT3 | P36888 | 5/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CCND1 | P24385 | 1/20 | 0.30 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21593360 | 0.83 | PRMT5 (0.40) | ALBKITKDRFLT3PRMT5 | |
| SCHEMBL23103599 | 0.83 | FLT3 (0.42) | KITKDRFLT3PRMT5WDR77 | |
| SCHEMBL24760193 | 0.80 | FLT3 (0.34) | KITKDRFLT3PRMT5WDR77 | |
| SCHEMBL23108967 | 0.80 | KIT (0.42) | ALBKITKDRFLT3CSF1R | |
| SCHEMBL23103608 | 0.77 | CDK4 (0.46) | CDK4CCND1CDK6 | |
| SCHEMBL26816525 | 0.71 | KDR (0.37) | KDRFLT3 | |
| SCHEMBL23132921 | 0.71 | ALDH1A1 (0.53) | KDRFLT3PRMT5WDR77 | |
| SCHEMBL23103326 | 0.70 | KDR (0.40) | KDRFLT3PRMT5WDR77CSF1R | |
| SCHEMBL23103324 | 0.70 | FLT3 (0.40) | KITKDRFLT3PRMT5WDR77 | |
| SCHEMBL23103294 | 0.70 | PLK1 (0.39) | KDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402911-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402911-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | IL1A, TNF, IL6 | ALB 2476/4885KIT 151/4885KDR 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.